TG Therapeutics Inc at JPMorgan Healthcare Conference Transcript
All right. So we can get started. I'm Eric Joseph, senior biotech analyst with JPMorgan. And our next presenting company is TG Therapeutics. Presenting on behalf of the company is CEO Mike Weiss. The Q&A session we're doing in the room, there'll be mics circulating around for those who want to ask a question, and you can also submit them in the digital conference book, and I can work them in.
So with that, Mike. Thanks.
Thanks, Eric, and thanks, everyone, for joining us this morning. Before I get started, I just mentioned that I probably will be making some forward-looking statements. So I do encourage folks who are interested to review our public disclosure documents available on the Internet and the risk factors that go with those.
All right. So let's get started here. We've got exciting news that we announced about 1.5 weeks ago. Ublituximab, is our lead development product
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |